[How the therapy of cancer is changing].
Lopez
M
M
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors* / Q000502:physiology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D018844:Cyclin-Dependent Kinases / Q000502:physiology; D016213:Cyclins / Q000502:physiology; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D051231:Farnesyltranstransferase; D005786:Gene Expression Regulation; D011905:Genes, ras; D017354:Point Mutation; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000502:physiology*; D018631:ras Proteins / Q000502:physiology*
D000970:Antineoplastic Agents; D016213:Cyclins; D004791:Enzyme Inhibitors; D019883:Alkyl and Aryl Transferases; D051231:Farnesyltranstransferase; D020794:Receptor Protein-Tyrosine Kinases; D018844:Cyclin-Dependent Kinases; D018631:ras Proteins